{"id":"NCT02337738","sponsor":"Takeda","briefTitle":"A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-01-27","primaryCompletion":"2016-09-17","completion":"2016-09-17","firstPosted":"2015-01-14","resultsPosted":"2019-02-28","lastUpdate":"2022-03-02"},"enrollment":404,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"TVP-1012 1mg","otherNames":[]},{"type":"DRUG","name":"TVP-1012 0.5mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TVP-1012 1mg","type":"EXPERIMENTAL"},{"label":"TVP-1012 0.5mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.5 mg or 1 mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with wearing-off phenomenon.","primaryOutcome":{"measure":"Change From Baseline in Mean Daily OFF-time During Treatment Period","timeFrame":"From Baseline to Week 26","effectByArm":[{"arm":"Placebo","deltaMin":-0.51,"sd":0.167},{"arm":"TVP-1012 0.5 mg","deltaMin":-1.11,"sd":0.174},{"arm":"TVP-1012 1 mg","deltaMin":-1.35,"sd":0.177}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0006"},{"comp":"OG000 vs OG001","p":"0.0140"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":26},"locations":{"siteCount":57,"countries":["Japan"]},"refs":{"pmids":["35077474"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":141},"commonTop":["Nasopharyngitis","Dyskinesia","Fall","Contusion"]}}